ArticleTherapeutic advances in medical oncology2025
Radiotherapy combined with locoregional hyperthermia for oligoprogression in metastatic melanoma local control.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An integrative naturopathic oncology approach in metastatic malignant melanoma: two case reports.Frontiers in oncology · 2026Article
- Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial.Frontiers in oncology · 2026Article
- Efficacy of radiotherapy and radiotherapy with hyperthermia to delay change of systemic therapy in patients with metastatic melanoma.Clinical and translational radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The evidence base for the management of oligoprogression in metastatic melanoma (MM) is limited. To our knowledge, this study presents the first analysis of the local benefit (LB) of radiotherapy combined with hyperthermia during systemic treatment in this diagnosis. Methods: Patients with oligoprogressive MM who were treated with radiotherapy (RTH) combined with hyperthermia (HT) at a melanoma center between 2019 and 2023 were evaluated. Oligoprogression was defined as up to five progressive metastases. Inclusion criteria was the availability of dimensions assessment of the lesion subjected to RTH before and after treatment, patients without follow-up imaging after radiotherapy were excluded. The benefit of RTH + HT was evaluated in terms of local control (LC) rates and LB rates. LC was defined as the percentage of patients who met the Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria for stable disease (SD), partial response (PR), and complete response (CR). LB was defined as the proportion of patients who met the PR and CR criteria. In addition, overall survival (OS) rates were estimated. The association between Results: In total, 101 patients were included in the study, the median follow-up was 15.3 months (14-18 months). There were 56.4% Conclusion: Hyperthermia with radiotherapy is an effective treatment for patients with oligoprogressive melanoma. This approach has resulted in excellent LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.